Determining prostate cancer-specific death through quantification of stromogenic carcinoma area in prostatectomy specimens

American Journal of Pathology

Volumn 178, Issue 1, 2011, Pages 79-87

  Ayala, Gustavo E ^a   Muezzinoglu, Bahar ^a   Hammerich, Kai H ^a   Frolov, Anna ^a   Liu, Hao ^a   Scardino, Peter T ^b   Li, Rile ^a   Sayeeduddin, Mohammad ^a   Ittmann, Michael M ^a   Kadmon, Dov ^a   Miles, Brian J ^a   Wheeler, Thomas M ^a   Rowley, David R ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER RECURRENCE; CORRELATION COEFFICIENT; FOLLOW UP; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; NOMOGRAM; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; PROSTATECTOMY; REACTIVE STROMAL GRADE 3; STROMA; TUMOR MICROENVIRONMENT;

EID: 79251512318     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2010.09.042     Document Type: Article

References (55)

1. Crawford ED: Epidemiology of prostate cancer. Urology 2003, 62(6 Suppl 1):3-12
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43-66
3. Gleason DF: Histologic grading of prostate cancer: a perspective. Hum Pathol 1992, 23:273-279
4. Bostwick DG: Grading prostate cancer. Am J Clin Pathol 1994, 102: S38-S56
5. Spires SE, Cibull ML, Wood DP Jr, Miller S, Spires SM, Banks ER: Gleason histologic grading in prostatic carcinoma. Correlation of 18-gauge core biopsy with prostatectomy, Arch Pathol Lab Med 1994, 118:705-708
6. Steinberg DM, Sauvageot J, Piantadosi S, Epstein JI: Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol 1997, 21:566-576
7. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL: Update on the Gleason grading system for prostate cancer: results of an international consensus conference of urologic pathologists. Adv Anat Pathol 2006, 13:57-59
8. Bostwick DG: Staging prostate cancer-1997: current methods and limitations. Eur Urol 1997, 32 Suppl 3:2-14
9. Burke HB, Bostwick DG, Meiers I, Montironi R: Prostate cancer outcome: epidemiology and biostatistics. Anal Quant Cytol Histol 2005, 27:211-217
10. Khan MA, Partin AW: Partin tables: past and present. BJU Int 2003, 92:7-11
11. Stephenson AJ, Kattan MW: Nomograms for prostate cancer. BJU Int 2006, 98:39-46
12. Ayala G, Tuxhorn JA, Wheeler TM, Frolov A, Scardino PT, Ohori M, Wheeler M, Spitler J, Rowley DR: Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin Cancer Res 2003, 9:4792-4801
13. Tuxhorn JA, Ayala GE, Rowley DR: Reactive stroma in prostate cancer progression. J Urol 2001, 166:2472-2483 (Pubitemid 33065339)
14. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, Rowley DR: Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res 2002, 8:2912-2923
15. Tuxhorn JA, McAlhany SJ, Dang TD, Ayala GE, Rowley DR: Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model. Cancer Res 2002, 62:3298-3307
16. Yanagisawa N, Li R, Rowley D, Liu H, Kadmon D, Miles BJ, Wheeler TM, Ayala GE: Reprint of: Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy. Hum Pathol 2008, 39:282-291
17. Ayala G, Tuxhorn JA, Wheeler TM, Frolov A, Scardino PT, Ohori M, Wheeler M, Spitler J, Rowley DR: Reactive stroma as a predictor of biochemical free recurrence in prostate cancer. Clin Cancer Res 2003, 9:4792-4801
18. Dakhova O, Ozen M, Creighton CJ, Li R, Ayala G, Rowley D, Ittmann M: Global gene expression analysis of reactive stroma in prostate cancer. Clin Cancer Res 2009, 15:3979-3989
19. Ronnov-Jessen L, Petersen OW, Bissell MJ: Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol Rev 1996, 76:69-125
20. Gregoire M, Lieubeau B: The role of fibroblasts in tumor behavior. Cancer Metastasis Rev 1995, 14:339-350
21. Martin M, Pujuguet P, Martin F: Role of stromal myofibroblasts infiltrating colon cancer in tumor invasion. Pathol Res Pract 1996, 192: 712-717
22. Ayala GE, Dai H, Ittmann M, Li R, Powell M, Frolov A, Wheeler TM, Thompson TC, Rowley D: Growth and survival mechanisms associated with perineural invasion in prostate cancer. Cancer Res 2004, 64:6082-6090
23. Ayala GE, Dai H, Li R, Ittmann M, Thompson TC, Rowley D, Wheeler TM: Bystin in perineural invasion of prostate cancer. Prostate 2006, 66:266-272
24. Ayala GE, Wheeler TM, Shine HD, Schmelz M, Frolov A, Chakraborty S, Rowley D: In vitro dorsal root ganglia and human prostate cell line interaction: redefining perineural invasion in prostate cancer. Prostate 2001, 49:213-223
25. Cornell RJ, Rowley D, Wheeler T, Ali N, Ayala G: Neuroepithelial interactions in prostate cancer are enhanced in the presence of prostatic stroma. Urology 2003, 61:870-875 (Pubitemid 36384998)
26. Dai H, Li R, Wheeler T, Diaz de Vivar A, Frolov A, Tahir S, Agoulnik I, Thompson T, Rowley D, Ayala G: Pim-2 upregulation: biological implications associated with disease progression and perineural invasion in prostate cancer. Prostate 2005, 65:276-286
27. Maru N, Ohori M, Kattan MW, Scardino PT, Wheeler TM: Prognostic significance of the diameter of perineural invasion in radical prostatectomy specimens. Hum Pathol 2001, 32:828-833
28. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M: The AJCC Cancer Staging Manual, ed 6. New York, Springer, 2002
29. Yang G, Ayala G, De Marzo A, Tian W, Frolov A, Wheeler TM, Thompson TC, Harper JW: Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res 2002, 8:3419-3426
30. Villers A, McNeal JE, Freiha FS, Stamey TA: Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors. Cancer 1992, 70:2313-2318
31. Aihara M, Wheeler TM, Ohori M, Scardino PT: Heterogeneity of prostate cancer in radical prostatectomy specimens, Urology 1994, 43: 60-66; discussion 66-67
32. Luo J, Isaacs WB, Trent JM, Duggan DJ: Looking beyond morphology: cancer gene expression profiling using DNA microarrays. Cancer Invest 2003, 21:937-949
33. Roudier MP, True LD, Higano CS, Vesselle H, Ellis W, Lange P, Vessella RL: Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol 2003, 34:646-653
34. von Eschenbach AC: The biologic dilemma of early carcinoma of the prostate. Cancer 1996, 78:326-329
35. Ohori M, Wheeler TM, Dunn JK, Stamey TA, Scardino PT: The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol 1994, 152:1714-1720 (Pubitemid 24322613)
36. Goto Y, Ohori M, Arakawa A, Kattan MW, Wheeler TM, Scardino PT: Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol 1996, 156: 1059-1063
37. Epstein JI, Carmichael MJ, Partin AW, Walsh PC: Small high grade adenocarcinoma of the prostate in radical prostatectomy specimens performed for nonpalpable disease: pathogenetic and clinical implications. J Urol 1994, 151:1587-1592
38. Noguchi M, Stamey TA, McNeal JE, Yemoto CM: Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer, J Urol 2001, 166:104-109; discussion 109-110
39. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999, 281:1591-1597
40. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC: Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience, Urol Clin North Am 2001, 28:555-565
41. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ: Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 2004, 172:910-914
42. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT: Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002, 167:528-534
43. Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H: Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 2000, 164:101-105
44. Moul JW: Treatment of PSA only recurrence of prostate cancer after prior local therapy. Curr Pharm Des 2006, 12:785-798
45. Tuxhorn JA, McAlhany SJ, Yang F, Dang TD, Rowley DR: Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. Cancer Res 2002, 62:6021-6025 (Pubitemid 35244446)
46. Mitchell JA, Cooperberg MR, Elkin EP, Lubeck DP, Mehta SS, Kane CJ, Carroll PR: Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE. J Urol 2005, 173:1126-1131
47. Andrén O, Garmo H, Mucci L, Andersson SO, Johansson JE, Fall K: Incidence and mortality of incidental prostate cancer: a Swedish register-based study. Br J Cancer 2009, 100:170-173
48. Mucci LA, Pawitan Y, Demichelis F, Fall K, Stark JR, Adami HO, Andersson SO, Andrén O, Eisenstein A, Holmberg L, Huang W, Kantoff PW, Kim R, Perner S, Stampfer MJ, Johansson JE, Rubin MA: Testing a multigene signature of prostate cancer death in the Swedish Watchful Waiting Cohort. Cancer Epidemiol Biomarkers Prev 2008, 17:1682-1688
49. Nguyen PL, Chen MH, Catalona WJ, Moul JW, Sun L, D'Amico AV: Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors. Int J Radiat Oncol Biol Phys 2009, 73:659-664
50. Collin SM, Martin RM, Metcalfe C, Gunnell D, Albertsen PC, Neal D, Hamdy F, Stephens P, Lane JA, Moore R, Donovan J: Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol 2008, 9:445-452
51. Stephenson AJ, Kattan MW, Eastham JA, Bianco FJ Jr, Yossepowitch O, Vickers AJ, Klein EA, Wood DP, Scardino PT: Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009, 27:4300-4305
52. Andrén O, Fall K, Andersson SO, Rubin MA, Bismar TA, Karlsson M, Johansson JE, Mucci LA: MUC-1 gene is associated with prostate cancer death: a 20-year follow-up of a population-based study in Sweden. Br J Cancer 2007, 97:730-734
53. Bubendorf L, Tapia C, Gasser TC, Casella R, Grunder B, Moch H, Mihatsch MJ, Sauter G: Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer. Hum Pathol 1998, 29:949-954
54. Zellweger T, Ninck C, Mirlacher M, Annefeld M, Glass AG, Gasser TC, Mihatsch MJ, Gelmann EP, Bubendorf L: Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer. Prostate 2003, 55:20-29
55. Bubendorf L, Sauter G, Moch H, Schmid HP, Gasser TC, Jordan P, Mihatsch MJ: Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol 1996, 178:437-441